Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 1
2004 2
2005 6
2006 6
2007 9
2008 4
2009 8
2010 11
2011 14
2012 16
2013 16
2014 23
2015 18
2016 26
2017 26
2018 25
2019 19
2020 25
2021 28
2022 28
2023 25
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

294 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.
Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, Lin H, Loewenstein A, Mohan S, Pearce IA, Sakamoto T, Schlottmann PG, Silverman D, Sun JK, Wells JA, Willis JR, Tadayoni R; YOSEMITE and RHINE Investigators. Wykoff CC, et al. Lancet. 2022 Feb 19;399(10326):741-755. doi: 10.1016/S0140-6736(22)00018-6. Epub 2022 Jan 24. Lancet. 2022. PMID: 35085503 Clinical Trial.
Reply.
Shiraishi M, Murakami T, Higashi K. Shiraishi M, et al. Among authors: murakami t. J Hypertens. 2020 Jul;38(7):1389-1390. doi: 10.1097/HJH.0000000000002467. J Hypertens. 2020. PMID: 32502101 No abstract available.
Atherosclerosis and arteriosclerosis.
Murakami T. Murakami T. Hypertens Res. 2023 Jul;46(7):1810-1811. doi: 10.1038/s41440-023-01284-0. Epub 2023 Apr 18. Hypertens Res. 2023. PMID: 37072574 No abstract available.
Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial.
Shimura M, Kitano S, Ogata N, Mitamura Y, Oh H, Ochi H, Ohsawa S, Hirakata A; YOSEMITE and RHINE Investigators. Shimura M, et al. Jpn J Ophthalmol. 2023 May;67(3):264-279. doi: 10.1007/s10384-023-00979-8. Epub 2023 Mar 10. Jpn J Ophthalmol. 2023. PMID: 36897413 Free PMC article. Clinical Trial.
Central Blood Pressure Estimation.
Murakami T. Murakami T. J Atheroscler Thromb. 2023 Sep 1;30(9):1108-1110. doi: 10.5551/jat.ED229. Epub 2023 Mar 22. J Atheroscler Thromb. 2023. PMID: 36948636 Free PMC article. No abstract available.
Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials.
Wong TY, Haskova Z, Asik K, Baumal CR, Csaky KG, Eter N, Ives JA, Jaffe GJ, Korobelnik JF, Lin H, Murata T, Ruamviboonsuk P, Schlottmann PG, Seres AI, Silverman D, Sun X, Tang Y, Wells JA, Yoon YH, Wykoff CC; YOSEMITE and RHINE Investigators. Wong TY, et al. Ophthalmology. 2023 Dec 28:S0161-6420(23)00933-8. doi: 10.1016/j.ophtha.2023.12.026. Online ahead of print. Ophthalmology. 2023. PMID: 38158159 Free article.
Aortic root dilatation and aortic stiffness.
Murakami T, Shiraishi M, Niwa K. Murakami T, et al. J Hypertens. 2022 Jul 1;40(7):1431. doi: 10.1097/HJH.0000000000003124. J Hypertens. 2022. PMID: 35762482 No abstract available.
Systemic AA amyloidosis as a prion-like disorder.
Murakami T, Inoshima Y, Ishiguro N. Murakami T, et al. Virus Res. 2015 Sep 2;207:76-81. doi: 10.1016/j.virusres.2014.12.019. Epub 2014 Dec 19. Virus Res. 2015. PMID: 25533533 Review.
294 results